Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Domestic-focused branded pharmaceuticals and consumer healthcare company selling prescription drugs across acute and increasingly chronic therapies at affordable price points, with one of the industry's largest field forces reaching tier-2/3/4 towns. Consumer brands include Manforce (condoms), Prega News (pregnancy test kits), Gas-O-Fast and HealthOK. Acquired Bharat Serums and Vaccines (BSV) in 2024 to add a high-entry-barrier women's health/critical care portfolio.
Fourth-largest pharma company in the Indian domestic market by sales, with market-leading consumer brands in condoms and pregnancy kits.
Mankind Pharma Ltd. is a constituent of NIFTY 200, NIFTY 500, NIFTY HEALTHCARE, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY MIDCAP 50, NIFTY PHARMA. See where it sits on the market heatmap →
Consolidated annual figures taken from Mankind Pharma Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 46.35 | 49.28 | 47.75 |
| Book value / share (₹) | 401.19 | 353.08 | 239.04 |
| Return on equity | 11.6% | 13.6% | 20.0% |
| Return on capital employed | 12.7% | 10.8% | 21.7% |
| Operating margin | 19.1% | 19.6% | 20.7% |
| Net margin | 13.6% | 16.5% | 18.8% |
| EBITDA | ₹3,617 Cr | ₹3,018 Cr | ₹2,535 Cr |
| Free cash flow | ₹2,384 Cr | ₹1,893 Cr | ₹1,770 Cr |
| Total debt | ₹6,312 Cr | ₹8,511 Cr | ₹207 Cr |
| Debt to equity | 0.38 | 0.58 | 0.02 |
| Interest coverage | 4.3 | 5.6 | 63.7 |
| Current ratio | 1.10 | 1.27 | 3.14 |
| Shares outstanding | 41,28,00,000 | 41,26,00,000 | 40,05,88,000 |
Open the full income statement, balance sheet and cash flow for MANKIND →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.